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Accepted 9 March 2015The cost of medical interventions raises legitimate con-
cerns at both individual and societal levels. Patients and their
families must bear some or all of these costs, which their
budgets often cannot accommodate. Additionally, health
care systems operate within budgets and, thus, strive to
maximize the outcomes within that budget. It is, thus, not
only reasonable but also ethically responsible to be con-
cerned with the cost of delivery of health care. Medical in-
terventions involving a high upfront cost, such as allogeneic
hematopoietic cell transplantation (alloHCT), are particularly
troublesome and deserving of scrutiny. Paying for them
might be impossible or come at the expense of painful
tradeoffs [1]. However, it is not always true that high upfront
costs involve high overall costs. Indeed, in this issue of
Biology of Blood and Marrow Transplantation, Arnold et al. [2]
show that in the case of alloHCT for children with sickle cell
disease (SCD), what seems to be the higher cost alternative
constitutes a more economic path over a period of 3 years.
Though the higher cost alternative was deemed superior
on economic grounds when viewed over 3 years, it consti-
tutes a relatively short period of time, potentially under-
estimating the positive economic impact of this high cost
intervention. Importantly, there is evidence that the cost of
treating SCD increases signiﬁcantly during adult years.
Furthermore, when costs are instead calculated from charges
that include costs, anticipated proﬁts, and adjustments inDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2015.01.010.
Financial disclosure: See Acknowledgments on page 1150.
* Correspondence and reprint requests: John F. Tisdale, MD, Molecular
and Clinical Hematology Branch National Heart, Lung, and Blood Institute
National Institutes of Health, Building 10, Room 9N112, Besthesda, MD
20892.
E-mail address: johntis@mail.nih.gov (J.F. Tisdale)
1083-8791/ 2015 Pan American Health Organization. Published by Elsevier
Inc. on behalf of TheAmerican Society for Blood andMarrowTransplantation.
All rights reserved.
http://dx.doi.org/10.1016/j.bbmt.2015.03.007charges to cover for uncollected charges, annual charges for
an adult with SCD reach $231,050 [3]. Most importantly,
these annual charges were estimated to increase progres-
sively in the following way: $35,488 for ages 0 to 5; $56,576
for ages 6 to 10; $111,749 for ages 11 to 18; and $231,050 for
ages 19 to 50. As such, 3 years of pediatric costs do not show
the signiﬁcance of the savings that result from trans-
plantations for SCD patients, not just because of the accu-
mulation of costs but also because of the increase of yearly
costs over time. The latter results from the facts that SCD is a
chronic debilitating condition and organ damage becomes
more severe over time, and, thus, its management becomes
more and more costly.
This analysis also points to ways to make alloHCT for SCD
patients even more economically attractive. Indeed, signiﬁ-
cant contributors to the cost of the intervention included the
poor results obtained using cord blood grafts, the care
required for the treatment of graft-versus-host disease, and
treatment required for cytomegalovirus reactivation. Im-
provements in these 3 areas could substantially reduce the
cost of the intervention. Indeed, in our own experience with
adult patients undergoing nonmyeloablative peripheral
blood stem cell transplantations for severe SCD, in which
engraftment rates are high without graft-versus-host disease
and only rare cytomegalovirus reactivation [4], the median
cost is $147,595, which is 49% of the cost of a myeloablative
transplantation performed at our institution (personal
communication, Theresa Jerrusi). Moreover, the reduction in
the yearly hospitalization rate in adults observed in our
experience was from 3.23 in the year before transplantation,
to .63, .19, and .11 in the ﬁrst, second, and third years and
beyond after transplantation, respectively, which represent a
more drastic reduction than that presented for pediatric
patients. A similar analysis of costs for adults undergoing
nonmyeloablative transplantation would, therefore, likely
require only 1 year of follow-up to demonstrate its favor-
ability on economic grounds, superior to what currently
constitutes the standard of care in the pediatric setting.
However, on economic grounds alone, the earlier the trans-
plantation, the greater the savings, as the total lifetime
charges to someone with SCD living to age 50 was estimated
at over $8 million [3].
C. Saenz, J.F. Tisdale / Biol Blood Marrow Transplant 21 (2015) 1149e11521150It should, however, be pointed out that claiming that 1
course of action is less costly than the alternative is not
synonymous with claiming that it is cost effective. Cost
effectiveness presupposes a comparison not only of costs but
also of the resulting effects (ie, beneﬁts) of the courses of
actions that are compared. For that sake, the authors analyze
the quality of life (QOL) that results from alloHCT. The au-
thors demonstrate an improvement in this measure by
comparing to published data, although their data on pedi-
atric alloHCT patients does not yield a statistically signiﬁcant
increase in QOL. Oddly, the QOL measures do not differ
signiﬁcantly between the control subjects with SCD and the
unaffected siblings, which suggests that the instrument is
either not robust or that the QOL of pediatric patients is not
as bad as the QOL of adult SCD patients [5]. It is also not clear
whether the authors consider in their calculations the
decline in QOL that occurs in SCD over time [5]. Certainly, one
need only visit the clinic to see the profound debilitating
effects that this disorder produces and the equally profound
mitigating effects that a successful transplantation allows.
When comparing different courses of actions in terms of
costs and effects, it is crucial to take the long view. Yet, in the
case of chronic diseases, the same applies to risks. Prospec-
tive health-related burdens behave in the same way as pro-
spective economic burdens and prospective health-related
beneﬁts. Indeed, just as comparing the costs of an inter-
vention such as alloHCT to its alternative over a short dura-
tion of time can lead to the erroneous conclusion that it is too
costly, comparing the risks of that same intervention viewed
over a similarly short duration can lead to the erroneous
conclusion that it is too risky. This mistake can be made
when assessing the risks of an intervention, experimental or
otherwise. The problem is that the upfront risks of an
intervention along with its alternative are often applied to
the time frame of the intervention only, not to the timeframe
over which the intervention is designed to potentially pro-
tect from the harms of the underlying condition. And in thecase of chronic diseases, that is a long period of time. In a
somewhat extreme example, the shorter view has led to
widespread rejection of the use of high-dose cyclophos-
phamide and autologous hematopoietic cell transplantation
for type 1 diabetes because of its high upfront risks, despite
evidence for efﬁcacy over the long term [6]. If the risks of this
intervention were compared to the long-term risk of type 1
diabetes, its risk proﬁle might be considered acceptable.
In summary, chronic diseases exert their deleterious ef-
fects over the long term and interventions that seek to
change the inevitable course of chronic disease must be
viewed in that long term.ACKNOWLEDGMENTS
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